Class 4 caution in use- Gemcitabine 2g/52.6ml concentrate for solution for infusion

Hikma Farmacêutica (Portugal) S.A has informed the MHRA that the Patient Information Leaflet (PIL) contained within batch CB0033 of Gemcitabine 2g/52.6ml concentrate for solution for infusion does not contain the side effects of serious skin reactions.

MHRA drug alert Date: 04/09/25

MHRA drug alert link: Class 4 Medicines Defect Notification: Hikma Farmacêutica, Gemcitabine 2g/52.6ml concentrate for solution for infusion, EL(25)A/43 - GOV.UK

This is a caution in use only we are not accepting stock returns

further information

For medical information queries please telephone +351 21 960 8410, or email portugaleupharmacovigilance@hikma.com.

For all stock control enquiries please telephone +44 020 7399 2760, or email customerserviceuk@hikma.com

Field Safety notice- Medihoney products

Packaging failures were identified related to the MediHoney® Wound and Burn products

Date of recall 02/09/25

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Ipca Laboratories UK Limited, Various Products

Ipca Laboratories UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the products listed in this notification do not contain all the required safety information.

MHRA drug alert date 27/08/25

MHRA drug alert link:Class 4 Medicines Defect Notification: Ipca Laboratories UK Limited, Various Products, EL(25)A/42 - GOV.UK

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries and information on this product, please contact via email address:pharmacovigilance@ipcauk.com or via telephone: 08003685328

For stock control enquiries please contact via telephone: +44 (0)7446 189 936.

Class 4 caution in use - Fexofenadine Hydrochloride 120mg film-coated tablets Active

Class 4 caution in use - Fexofenadine Hydrochloride 120mg film-coated tablets

Chanelle Medical Unlimited Company has informed the MHRA of an error with the European Article Number (EAN) / Global Trade Item Number (GTIN) barcode on the cartons of the above batch of Fexofenadine Hydrochloride 120mg film-coated tablets, distributed by Healthcare Pharma Limited. When scanned, the EAN/GTIN barcode identifies the product as Naratriptan 2.5mg Tablets..
 
MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-notification-fexofenadine-hydrochloride-120mg-film-coated-tablets-chanelle-medical-unlimited-company-el-25-a-slash-41?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=6190b8e4-635d-43ca-b371-997872fb962f&utm_content=immediately

MHRA drug alert date: 21/08/25

This is a caution in use only we are not accepting stock returns
 
For all medical information enquiries and information on this product, please contact Medical Information Department chanelle@medinformation.co.uk or telephone +44 808 304 2429 (Toll free-UK).

For stock control enquiries please email David Hammond: david.hammond@healthcarepharma.co.uk. Recipients of this Medicines Recall should bring.

Class 4 caution in use - Levetiracetam Accord 100mg/ml oral solution

Accord Healthcare Limited, UK has informed the MHRA that the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC) do not contain all the required safety information.
 
MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-notification-levetiracetam-accord-100mg-slash-ml-oral-solution-accord-healthcare-limited-uk-el-25-a-slash-40?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=9f75ebd8-3b27-4733-8087-29486e7f8a54&utm_content=immediately

MHRA drug alert date: 14/08/25

This is a caution in use only we are not accepting stock returns
 
For medical information enquiries please contact:

Accord Medical Information Department on 01271 385257, email- medinfo@accord-healthcare.com.

For stock control enquiries please contact: Accord- Customer Services Team on 0800 373573.

Class 4 caution in use-Topiramate 20mg/ml oral solution

Zydus Pharmaceuticals UK LTD has informed the MHRA that there is an error on the artwork for the outer carton and Patient Information Leaflet (PIL) of Topiramate Zydus Pharmaceuticals UK 20mg/ml Oral Solution (pack size 150ml and 280ml bottles).

MHRA drug alert link:Class 4 Medicines Defect Notification: Topiramate Zydus Pharmaceuticals UK 20mg/ml Oral Solution, Zydus Pharmaceuticals UK Ltd, EL(25)A/39 - GOV.UK

MHRA drug alert date:07/08/25

This is a caution in use only we are not accepting stock returns

Further Information

For all enquires on this product please email DrugSafety@ZydusUK.com or telephone 0800 9956034.

Class 2 recall-Fucidin 250mg tabs

LEO Pharma is recalling the affected batch as a precautionary measure due to out of specification results for impurities during routine stability testing.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-fucidin-250-mg-tablets-leo-laboratories-ltd-trading-as-leo-pharma-el-25-a-slash-38

MHRA drug alert date: 02/08/25

Further Information

For all enquiries and information on this product, please email medical-info.uk@leo-pharma.com or telephone 01844 347 333 and press 2 for Medical Information.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

August 2025 bank holiday opening hours

To help keep our customers informed of changes to our service, we have published our August 2025 bank holiday opening hours for pharmacy and retail customers.

August 2025 bank holiday opening hours

August 2025 bank holiday opening hours (for Channel Islands and Isle of Man)

Class 4 Caution in use-Olmesartan medoxomil 10mg film-coated tablets, Jubilant Pharmaceuticals

Jubilant Pharmaceuticals NV has informed the MHRA that the Patient Information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.

MHRA drug alert link:Class 4 Medicines Defect Notification: Olmesartan medoxomil 10mg film-coated tablets, Jubilant Pharmaceuticals NV, EL(25)A/37 - GOV.UK

MHRA drug alert date:31/07/25

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please email safety.uk@lambda-cro.com, or telephone  0800 0668348.

For stock control enquiries please email JPUK.Customerservice@jubl.com, or telephone 01233 552293

Class 2 recall-Flutiform 250/10mg (Alliance healthcare do not stock)

CD Pharma Ltd have notified the MHRA of an error on the outer carton of the product for the batches listed in this notification. While the total active content statement is correct, the delivered dose content statement is incorrect. The other details on the carton are correct.

Drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-flutiform-250-micrograms-slash-10-micrograms-per-actuation-pressurised-inhalation-suspension-cd-pharma-ltd-el-25-a-slash-35?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=a726e5d4-c8e3-40a1-8762-ec99de3f74bb&utm_content=immediately

drug alert date: 24/07/25

Further Information

For all further enquiries please contact 01355 204 448 or email regaffairs@teleta.co.uk

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.